- For heart failure (HF) with reduced ejection fraction (HFrEF), vericiguat yields reductions in cardiovascular death and hospitalization among patients needing urgent care.
- Number needed to treat was identified in this trial as about 24 patients.
Why this matters
- These patients who have recent decompensated HF need treatment options that ameliorate a potentially poor prognosis.
- Median follow-up, 10.8 months.
- 35.5% of patients in the drug group vs 38.5% in placebo had the primary outcome of cardiovascular death or first HF hospitalization.
- HR, 0.90 (95% CI, 0.82-0.98).
- HF hospitalization rates were 27.4% with vericiguat vs 29.6% with placebo.
- HR, 0.90 (95% CI, 0.81-1.00).
- Cardiovascular death rates were 16.4% with the drug vs 17.5% with placebo.
- HR, 0.93 (95% CI, 0.81-1.06).
- Adverse events included symptomatic hypotension (9.1% drug vs 7.9% placebo) and syncope (4.0% drug vs 3.5% placebo) and did not differ significantly between groups.
- Anemia was more common with drug vs placebo: 7.6% vs 5.7%.
- 1.6% vs 0.9% were considered serious.
- Phase 3 randomized, double-blind, placebo-controlled trial, enrolling 5050 patients from September 25, 2016 to December 21, 2018 at 616 sites in 42 countries.
- Funding: MSD; Bayer.
- Role of vericiguat in those taking drugs for diabetes was not addressed.